Higher serum levels of osteoglycin are associated with all-cause mortality and cardiovascular and cerebrovascular events in patients with advanced chronic kidney disease

Seon Ha Baek, Ran Hui Cha, Shin Wook Kang, Cheol Whee Park, Dae-Ryong Cha, Sung Gyun Kim, Sun Ae Yoon, Sejoong Kim, Sang Youb Han, Jung Hwan Park, Jae Hyun Chang, Chun Soo Lim, Yon Su Kim, Ki Young Na

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Patients with chronic kidney disease (CKD) have markedly increased rates of major adverse cardiovascular and cerebrovascular events (MACCEs) and mortality. Therefore, identifying early biomarkers predicting clinical outcomes in patients with CKD is critical. We aimed to determine whether osteoglycin, a basic component of the vascular extracellular matrix, was associated with MACCEs or all-cause mortality, using data from a prospective randomized controlled study, K-STAR (Kremezin STudy Against Renal disease progression in Korea: NCT 00860431). A total of 383 patients (mean age: 56.4 years, men/women =252/131) with CKD stage 3 to 4 from the original trial were enrolled in the present study. We measured serum osteoglycin level and examined the impact of osteoglycin on clinical outcomes. The mean value of osteoglycin levels was 13.3 ± 9.4 ng/mL (healthy control: 5.3 ± 2.1 ng/mL). In multivariable analysis, lower levels of proteinuria and hemoglobin and higher levels of C-reactive protein were significantly associated with higher osteoglycin levels. Estimated glomerular filtration rate was not related to osteoglycin level. During a mean follow-up period of 56 months, 25 deaths, 61 MACCEs, and 76 composite outcomes (all-cause mortality or MACCEs) occurred. In the non-diabetic group, each 1-ng/mL increase in serum osteoglycin was associated with all-cause mortality and composite outcome (hazard ratio [HR] = 1.058, P = 0.031; HR = 1.041, P = 0.036). However, osteoglycin levels were not associated with mortality, MACCEs, or composite outcome in the diabetic group. Our results indicate that serum osteoglycin is a potential predictor of adverse outcomes in patients with CKD.

Original languageEnglish
Pages (from-to)281-290
Number of pages10
JournalTohoku Journal of Experimental Medicine
Volume242
Issue number4
DOIs
Publication statusPublished - 2017 Aug 1

Fingerprint

Chronic Renal Insufficiency
Mortality
Serum
Hazards
Composite materials
Biomarkers
Korea
Glomerular Filtration Rate
Proteinuria
C-Reactive Protein
Extracellular Matrix
Blood Vessels
Disease Progression
Hemoglobins
Kidney

Keywords

  • All-cause mortality
  • Biomarker
  • Chronic kidney disease
  • Diabetes mellitus
  • Osteoglycin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Higher serum levels of osteoglycin are associated with all-cause mortality and cardiovascular and cerebrovascular events in patients with advanced chronic kidney disease. / Baek, Seon Ha; Cha, Ran Hui; Kang, Shin Wook; Park, Cheol Whee; Cha, Dae-Ryong; Kim, Sung Gyun; Yoon, Sun Ae; Kim, Sejoong; Han, Sang Youb; Park, Jung Hwan; Chang, Jae Hyun; Lim, Chun Soo; Kim, Yon Su; Na, Ki Young.

In: Tohoku Journal of Experimental Medicine, Vol. 242, No. 4, 01.08.2017, p. 281-290.

Research output: Contribution to journalArticle

Baek, Seon Ha ; Cha, Ran Hui ; Kang, Shin Wook ; Park, Cheol Whee ; Cha, Dae-Ryong ; Kim, Sung Gyun ; Yoon, Sun Ae ; Kim, Sejoong ; Han, Sang Youb ; Park, Jung Hwan ; Chang, Jae Hyun ; Lim, Chun Soo ; Kim, Yon Su ; Na, Ki Young. / Higher serum levels of osteoglycin are associated with all-cause mortality and cardiovascular and cerebrovascular events in patients with advanced chronic kidney disease. In: Tohoku Journal of Experimental Medicine. 2017 ; Vol. 242, No. 4. pp. 281-290.
@article{10da1f1ee3bf4b05bb1cf75421157075,
title = "Higher serum levels of osteoglycin are associated with all-cause mortality and cardiovascular and cerebrovascular events in patients with advanced chronic kidney disease",
abstract = "Patients with chronic kidney disease (CKD) have markedly increased rates of major adverse cardiovascular and cerebrovascular events (MACCEs) and mortality. Therefore, identifying early biomarkers predicting clinical outcomes in patients with CKD is critical. We aimed to determine whether osteoglycin, a basic component of the vascular extracellular matrix, was associated with MACCEs or all-cause mortality, using data from a prospective randomized controlled study, K-STAR (Kremezin STudy Against Renal disease progression in Korea: NCT 00860431). A total of 383 patients (mean age: 56.4 years, men/women =252/131) with CKD stage 3 to 4 from the original trial were enrolled in the present study. We measured serum osteoglycin level and examined the impact of osteoglycin on clinical outcomes. The mean value of osteoglycin levels was 13.3 ± 9.4 ng/mL (healthy control: 5.3 ± 2.1 ng/mL). In multivariable analysis, lower levels of proteinuria and hemoglobin and higher levels of C-reactive protein were significantly associated with higher osteoglycin levels. Estimated glomerular filtration rate was not related to osteoglycin level. During a mean follow-up period of 56 months, 25 deaths, 61 MACCEs, and 76 composite outcomes (all-cause mortality or MACCEs) occurred. In the non-diabetic group, each 1-ng/mL increase in serum osteoglycin was associated with all-cause mortality and composite outcome (hazard ratio [HR] = 1.058, P = 0.031; HR = 1.041, P = 0.036). However, osteoglycin levels were not associated with mortality, MACCEs, or composite outcome in the diabetic group. Our results indicate that serum osteoglycin is a potential predictor of adverse outcomes in patients with CKD.",
keywords = "All-cause mortality, Biomarker, Chronic kidney disease, Diabetes mellitus, Osteoglycin",
author = "Baek, {Seon Ha} and Cha, {Ran Hui} and Kang, {Shin Wook} and Park, {Cheol Whee} and Dae-Ryong Cha and Kim, {Sung Gyun} and Yoon, {Sun Ae} and Sejoong Kim and Han, {Sang Youb} and Park, {Jung Hwan} and Chang, {Jae Hyun} and Lim, {Chun Soo} and Kim, {Yon Su} and Na, {Ki Young}",
year = "2017",
month = "8",
day = "1",
doi = "10.1620/tjem.242.281",
language = "English",
volume = "242",
pages = "281--290",
journal = "Tohoku Journal of Experimental Medicine",
issn = "0040-8727",
publisher = "Tohoku University Medical Press",
number = "4",

}

TY - JOUR

T1 - Higher serum levels of osteoglycin are associated with all-cause mortality and cardiovascular and cerebrovascular events in patients with advanced chronic kidney disease

AU - Baek, Seon Ha

AU - Cha, Ran Hui

AU - Kang, Shin Wook

AU - Park, Cheol Whee

AU - Cha, Dae-Ryong

AU - Kim, Sung Gyun

AU - Yoon, Sun Ae

AU - Kim, Sejoong

AU - Han, Sang Youb

AU - Park, Jung Hwan

AU - Chang, Jae Hyun

AU - Lim, Chun Soo

AU - Kim, Yon Su

AU - Na, Ki Young

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Patients with chronic kidney disease (CKD) have markedly increased rates of major adverse cardiovascular and cerebrovascular events (MACCEs) and mortality. Therefore, identifying early biomarkers predicting clinical outcomes in patients with CKD is critical. We aimed to determine whether osteoglycin, a basic component of the vascular extracellular matrix, was associated with MACCEs or all-cause mortality, using data from a prospective randomized controlled study, K-STAR (Kremezin STudy Against Renal disease progression in Korea: NCT 00860431). A total of 383 patients (mean age: 56.4 years, men/women =252/131) with CKD stage 3 to 4 from the original trial were enrolled in the present study. We measured serum osteoglycin level and examined the impact of osteoglycin on clinical outcomes. The mean value of osteoglycin levels was 13.3 ± 9.4 ng/mL (healthy control: 5.3 ± 2.1 ng/mL). In multivariable analysis, lower levels of proteinuria and hemoglobin and higher levels of C-reactive protein were significantly associated with higher osteoglycin levels. Estimated glomerular filtration rate was not related to osteoglycin level. During a mean follow-up period of 56 months, 25 deaths, 61 MACCEs, and 76 composite outcomes (all-cause mortality or MACCEs) occurred. In the non-diabetic group, each 1-ng/mL increase in serum osteoglycin was associated with all-cause mortality and composite outcome (hazard ratio [HR] = 1.058, P = 0.031; HR = 1.041, P = 0.036). However, osteoglycin levels were not associated with mortality, MACCEs, or composite outcome in the diabetic group. Our results indicate that serum osteoglycin is a potential predictor of adverse outcomes in patients with CKD.

AB - Patients with chronic kidney disease (CKD) have markedly increased rates of major adverse cardiovascular and cerebrovascular events (MACCEs) and mortality. Therefore, identifying early biomarkers predicting clinical outcomes in patients with CKD is critical. We aimed to determine whether osteoglycin, a basic component of the vascular extracellular matrix, was associated with MACCEs or all-cause mortality, using data from a prospective randomized controlled study, K-STAR (Kremezin STudy Against Renal disease progression in Korea: NCT 00860431). A total of 383 patients (mean age: 56.4 years, men/women =252/131) with CKD stage 3 to 4 from the original trial were enrolled in the present study. We measured serum osteoglycin level and examined the impact of osteoglycin on clinical outcomes. The mean value of osteoglycin levels was 13.3 ± 9.4 ng/mL (healthy control: 5.3 ± 2.1 ng/mL). In multivariable analysis, lower levels of proteinuria and hemoglobin and higher levels of C-reactive protein were significantly associated with higher osteoglycin levels. Estimated glomerular filtration rate was not related to osteoglycin level. During a mean follow-up period of 56 months, 25 deaths, 61 MACCEs, and 76 composite outcomes (all-cause mortality or MACCEs) occurred. In the non-diabetic group, each 1-ng/mL increase in serum osteoglycin was associated with all-cause mortality and composite outcome (hazard ratio [HR] = 1.058, P = 0.031; HR = 1.041, P = 0.036). However, osteoglycin levels were not associated with mortality, MACCEs, or composite outcome in the diabetic group. Our results indicate that serum osteoglycin is a potential predictor of adverse outcomes in patients with CKD.

KW - All-cause mortality

KW - Biomarker

KW - Chronic kidney disease

KW - Diabetes mellitus

KW - Osteoglycin

UR - http://www.scopus.com/inward/record.url?scp=85029404512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029404512&partnerID=8YFLogxK

U2 - 10.1620/tjem.242.281

DO - 10.1620/tjem.242.281

M3 - Article

VL - 242

SP - 281

EP - 290

JO - Tohoku Journal of Experimental Medicine

JF - Tohoku Journal of Experimental Medicine

SN - 0040-8727

IS - 4

ER -